Sarepta Therapeutics Inc’s filing revealed that its Director Wigzell Hans Lennart Rudolf unloaded Company’s shares for reported $1.31 million on Dec 12 ’24. In the deal valued at $124.84 per share,10,500 shares were sold. As a result of this transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares worth roughly $2.3 million.
Then, Wigzell Hans Lennart Rudolf bought 10,500 shares, generating $1,310,400 in total proceeds.
Before that, Boor Kathryn Jean sold 1,636 shares. Sarepta Therapeutics Inc shares valued at $205,400 were divested by the Director at a price of $125.55 per share. As a result of the transaction, Boor Kathryn Jean now holds 5,880 shares, worth roughly $0.59 million.
Deutsche Bank initiated its Sarepta Therapeutics Inc [SRPT] rating to a Hold in a research note published on February 11, 2025; the price target was $136. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in late November has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering SRPT with “Sell” recommendation on November 25, 2024. Cantor Fitzgerald revised its rating on November 07, 2024. It rated SRPT as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of SRPT
On Tuesday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock jump 1.02% to $100.71. Over the last five days, the stock has lost -2.09%. Sarepta Therapeutics Inc shares have fallen nearly -17.17% since the year began. Nevertheless, the stocks have fallen -16.62% over the past one year. While a 52-week high of $173.25 was reached on 01/07/25, a 52-week low of $98.82 was recorded on 03/11/25. SMA at 50 days reached $113.54, while 200 days put it at $126.36.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 98.56, which if violated will result in even more drops to 96.41. On the upside, there is a resistance level at 102.21. A further resistance level may holdings at 103.71. The Relative Strength Index (RSI) on the 14-day chart is 38.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.84%. Stochastics %K at 21.52% indicates the stock is a holding.
The most recent change occurred on October 21, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $165 price target.
